1. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. (March 2016) Authors: Abraham, Bincy; Wolf, Doug; Regueiro, Miguel; Randall, Charles; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-106 Examination of an Alternative Definition for Clinical Remission in UC: Results from TOUCHSTONE, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod. (March 2016) Authors: Sandborn, William; Feagan, Brian; D'Haens, Geert; Wolf, Doug; Vermeire, Severine; Hanauer, Stephen; Ghosh, Subrata; Smith, Heather; Cravets, Matthew; Frohna, Paul; Aranda, Richard; Gujrathi, Sheila; Olson, Allan Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-104 SECURE: An Observational Study of Certolizumab Pegol in Crohn's Disease—Events of Interest Analysis with 5869 Patient-Years at Risk. (March 2016) Authors: Lee, Scott; Wolf, Doug; Feagan, Brian; Lichtenstein, Gary; Andrews, Elizabeth; Stidham, Ryan; Aberra, Faten; Aguilar, Humberto; Kayhan, Cem; Kosutic, Gordana; Sen, David; Golembesky, Amanda; Hasan, Iram; Spearman, Marshall; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-020 Clinical Outcomes Associated with Non-medical Switching or Discontinuation of Anti-TNF Inhibitors Among Patients with Inflammatory Bowel Disease. (March 2016) Authors: Wolf, Doug; Skup, Martha; Yang, Hongbo; Faust, Elizabeth; Fang, Anna; Chao, Jingdong; Lebwohl, Mark Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Challenges in Using Real‐World Clinical Practice Records for Retrospective Validation of Clinical Trial Data: Lessons Learned: 722. (October 2016) Authors: Kane, Sunanda V.; Afzali, Anita; Wolf, Doug; Shafran, Ira; Ciorba, Matthew A.; Ritter, Timothy E.; Sharaf, Mai; Fourment, Christopher; Kosutic, Gordana; Coarse, Jason; Randall, Charles W. Journal: American journal of gastroenterology Issue: Volume 111(2016)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and Efficacy of Long‐Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension: 571. (October 2016) Authors: Sandborn, William J.; Feagan, Brian; D'Haens, Geert; Hanauer, Stephen; Wolf, Doug; Vermeire, Séverine; Ghosh, Subrata; Smith, Heather; Cravets, Matt; Frohna, Paul A.; Aranda, Richard; Olson, Allan Journal: American journal of gastroenterology Issue: Volume 111(2016)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-106 Examination of an Alternative Definition for Clinical Remission in UC: Results from TOUCHSTONE, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod. (March 2016) Authors: Sandborn, William; Feagan, Brian; D'Haens, Geert; Wolf, Doug; Vermeire, Severine; Hanauer, Stephen; Ghosh, Subrata; Smith, Heather; Cravets, Matthew; Frohna, Paul; Aranda, Richard; Gujrathi, Sheila; Olson, Allan Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-020 Clinical Outcomes Associated with Non-medical Switching or Discontinuation of Anti-TNF Inhibitors Among Patients with Inflammatory Bowel Disease. (March 2016) Authors: Wolf, Doug; Skup, Martha; Yang, Hongbo; Faust, Elizabeth; Fang, Anna; Chao, Jingdong; Lebwohl, Mark Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids: Pooled Safety Data from 15 Clinical Trials. (March 2016) Authors: Abraham, Bincy; Wolf, Doug; Regueiro, Miguel; Randall, Charles; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-104 SECURE: An Observational Study of Certolizumab Pegol in Crohn's Disease—Events of Interest Analysis with 5869 Patient-Years at Risk. (March 2016) Authors: Lee, Scott; Wolf, Doug; Feagan, Brian; Lichtenstein, Gary; Andrews, Elizabeth; Stidham, Ryan; Aberra, Faten; Aguilar, Humberto; Kayhan, Cem; Kosutic, Gordana; Sen, David; Golembesky, Amanda; Hasan, Iram; Spearman, Marshall; Loftus, Edward Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗